FindTrial
Sign In

Effectiveness in the reduction of Dentin Hypersensitivity and assessment of quality of life in patients using 8% Arginine-based toothpaste and low-intensity laser: interventional study

Efficacy in reducing dentin hypersensitivity and assessing quality of life in patients using 8% arginine-based dentifrices and laser photobiomodulation of low intensity. Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2vxzvkz
Enrollment
Unknown
Registered
2023-10-13
Start date
2022-06-04
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentin sensitivity

Interventions

Randomized controled clinical trial, paralell, double-blind with 4 experimental groups (warms): placebo (Colgate maximum caries protection and laser beep)
8% arginine group (Colgate traditional pro-relief)
arginine and low-level laser group (8% arginine, photon laser III use for 84 seconds) and low-level laser group (photon laser III for 84 seconds). Each group will have 21 participants. The trial perio
E02.594.540

Sponsors

Universidade Luterana do Brasil
Lead Sponsor
Universidade Luterana do Brasil
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals must be at least 18 years old; clear clinical presence of alterations such as abrasion, attrition and erosion in anterior and/or posterior teeth; present hypersensitivity in two non-adjacent teeth; response to air jet stimulus for one second in the cervical region, as defined by score 2 or 3 on the Schiff scale, for sensitivity to air stimulus; visible plaque index and gingival bleeding index less than 20%.

Exclusion criteria

Exclusion criteria: Individuals with allergies to any product to be tested; individuals with clinical presence of serious pathologies in the soft tissues; individuals undergoing chemotherapy and radiotherapy; individuals with gingivitis and/or periodontitis; subjects who started taking anticonvulsants, antihistamines, sedatives, tranquilizers, anti-depressive, anti-inflammatory or analgesic drugs within one month before the start of the study or who would start taking them during the study; subjects who took antibiotics up to three months before the study; individuals who are participating in another study; pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Reduction of dentin hypersensitivity, by reducing the Schiff score and Visual analogue scale (pain scale).—

Secondary

MeasureTime frame
To evaluate Oral health related quality of life through Oral Health Impact Profile Simplified (OHIP-14); To evaluate supragingival parameters (Visible plaque index and Gingival bleeding index) through periodontal probe with a Williams' periodontal probe.—

Countries

Brazil

Contacts

Public ContactViviane Barbosa

Universidade Luterana do Brasil

vivianebarbosa.mk@gmail.com+55 (51) 34629512

Outcome results

None listed

Source: REBEC (via WHO ICTRP)